Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Greenviolinoon Jan 14, 2021 11:19am
151 Views
Post# 32294176

RE:RE:RE:RE:RE:RE:Placement

RE:RE:RE:RE:RE:RE:Placement

@archeo.

A bought-deal means that the lead broker is writing a check to the company. Therefore the broker is on the hook for any shares that it cannot place. It also explains why the commission on such deals is higher. Give Mackie some credit for having found buyers for the share offering.
The stock is under pressure now because the issue is probably not completely sold yet. Tomorow will be a strong test because settlement of the issue is Jan19. Speculators will sell if they don't make a quick buck. If the stock doesn't move much within the next week, this will tell us that Mackie still has shares to place. So for those complaining they were not contacted to partipate, you have an opportunity to currently buy below issue price in the market. Now, who wants to debate whether this  financing is worse than the convertible debt issue done a couple of years ago? 

<< Previous
Bullboard Posts
Next >>